Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 23

1.

Phase 1 randomized trial of the vaginal safety and acceptability of SPL7013 gel (VivaGel) in sexually active young women (MTN-004).

McGowan I, Gomez K, Bruder K, Febo I, Chen BA, Richardson BA, Husnik M, Livant E, Price C, Jacobson C; MTN-004 Protocol Team..

AIDS. 2011 May 15;25(8):1057-64. doi: 10.1097/QAD.0b013e328346bd3e.

2.

A phase I randomized placebo controlled trial of the safety of 3% SPL7013 Gel (VivaGel®) in healthy young women administered twice daily for 14 days.

Cohen CR, Brown J, Moscicki AB, Bukusi EA, Paull JR, Price CF, Shiboski S.

PLoS One. 2011 Jan 20;6(1):e16258. doi: 10.1371/journal.pone.0016258.

3.

Increased levels of immune activation in the genital tract of healthy young women from sub-Saharan Africa.

Cohen CR, Moscicki AB, Scott ME, Ma Y, Shiboski S, Bukusi E, Daud I, Rebbapragada A, Brown J, Kaul R.

AIDS. 2010 Aug 24;24(13):2069-74. doi: 10.1097/QAD.0b013e32833c323b.

4.

IL-13 and the IL-13 receptor as therapeutic targets for asthma and allergic disease.

Mitchell J, Dimov V, Townley RG.

Curr Opin Investig Drugs. 2010 May;11(5):527-34. Review.

PMID:
20419598
5.

HIV infection in the female genital tract: discrete influence of the local mucosal microenvironment.

Kaushic C, Ferreira VH, Kafka JK, Nazli A.

Am J Reprod Immunol. 2010 Jun;63(6):566-75. doi: 10.1111/j.1600-0897.2010.00843.x. Epub 2010 Mar 29. Review.

PMID:
20384619
6.

Safety analysis of the diaphragm in combination with lubricant or acidifying microbicide gels: effects on markers of inflammation and innate immunity in cervicovaginal fluid.

Anderson DJ, Williams DL, Ballagh SA, Barnhart K, Creinin MD, Newman DR, Bowman FP, Politch JA, Duerr AC, Jamieson DJ.

Am J Reprod Immunol. 2009 Feb;61(2):121-9. doi: 10.1111/j.1600-0897.2008.00670.x.

PMID:
19143675
7.

A new strategy to understand how HIV infects women: identification of a window of vulnerability during the menstrual cycle.

Wira CR, Fahey JV.

AIDS. 2008 Oct 1;22(15):1909-17. doi: 10.1097/QAD.0b013e3283060ea4. Review. No abstract available.

8.

Mucosal innate immunity as a determinant of HIV susceptibility.

Iqbal SM, Kaul R.

Am J Reprod Immunol. 2008 Jan;59(1):44-54. Review.

PMID:
18154595
9.

No increase in cervicovaginal proinflammatory cytokines after Carraguard use in a placebo-controlled randomized clinical trial.

Bollen LJ, Blanchard K, Kilmarx PH, Chaikummao S, Connolly C, Wasinrapee P, Srivirojana N, Achalapong J, Tappero JW, McNicholl JM.

J Acquir Immune Defic Syndr. 2008 Feb 1;47(2):253-7.

PMID:
18025996
10.

A comprehensive murine model to evaluate topical vaginal microbicides: mucosal inflammation and susceptibility to genital herpes as surrogate markers of safety.

Galen BT, Martin AP, Hazrati E, Garin A, Guzman E, Wilson SS, Porter DD, Lira SA, Keller MJ, Herold BC.

J Infect Dis. 2007 May 1;195(9):1332-9. Epub 2007 Mar 19.

PMID:
17397004
11.

Fourteen-day safety and acceptability study of 6% cellulose sulfate gel: a randomized double-blind Phase I safety study.

Schwartz JL, Mauck C, Lai JJ, Creinin MD, Brache V, Ballagh SA, Weiner DH, Hillier SL, Fichorova RN, Callahan M.

Contraception. 2006 Aug;74(2):133-40. Epub 2006 May 2.

PMID:
16860051
12.
13.

Vaginal microbicides: detecting toxicities in vivo that paradoxically increase pathogen transmission.

Cone RA, Hoen T, Wong X, Abusuwwa R, Anderson DJ, Moench TR.

BMC Infect Dis. 2006 Jun 1;6:90.

14.
15.

PRO 2000 gel inhibits HIV and herpes simplex virus infection following vaginal application: a double-blind placebo-controlled trial.

Keller MJ, Zerhouni-Layachi B, Cheshenko N, John M, Hogarty K, Kasowitz A, Goldberg CL, Wallenstein S, Profy AT, Klotman ME, Herold BC.

J Infect Dis. 2006 Jan 1;193(1):27-35. Epub 2005 Nov 17.

PMID:
16323128
16.

Detection of implantation-related cytokines in cervicovaginal secretions and peripheral blood of fertile women during ovulatory menstrual cycles.

Gargiulo AR, Fichorova RN, Politch JA, Hill JA, Anderson DJ.

Fertil Steril. 2004 Oct;82 Suppl 3:1226-34.

PMID:
15474100
17.

Interleukin (IL)-1, IL-6, and IL-8 predict mucosal toxicity of vaginal microbicidal contraceptives.

Fichorova RN, Bajpai M, Chandra N, Hsiu JG, Spangler M, Ratnam V, Doncel GF.

Biol Reprod. 2004 Sep;71(3):761-9. Epub 2004 May 5.

PMID:
15128598
18.

Mucosal immunity of the adolescent female genital tract.

Shrier LA, Bowman FP, Lin M, Crowley-Nowick PA.

J Adolesc Health. 2003 Mar;32(3):183-6.

PMID:
12606111
19.

Effectiveness of COL-1492, a nonoxynol-9 vaginal gel, on HIV-1 transmission in female sex workers: a randomised controlled trial.

Van Damme L, Ramjee G, Alary M, Vuylsteke B, Chandeying V, Rees H, Sirivongrangson P, Mukenge-Tshibaka L, Ettiègne-Traoré V, Uaheowitchai C, Karim SS, Mâsse B, Perriëns J, Laga M; COL-1492 Study Group..

Lancet. 2002 Sep 28;360(9338):971-7. Erratum in: Lancet 2002 Dec 7;360(9348):1892.

PMID:
12383665
20.

Regulation of IL-5 expression.

Mordvinov VA, Sanderson CJ.

Arch Immunol Ther Exp (Warsz). 2001;49(5):345-51. Review.

PMID:
11798132

Supplemental Content

Support Center